Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

BPC-157

Body Protection Compound-157, PL-14736, Pentadecapeptide BPC 157

Quick Stats
Studies 196
Trials 1
Score 3
2015 pubmed 64 citations

Pentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine.

Stupnisek. Mirjana M; Kokot. Antonio A; Drmic. Domagoj D; Hrelec Patrlj. Masa M; Zenko Sever. Anita A; Kolenc. Danijela D; Radic. Bozo B; Suran. Jelena J; Bojic. Davor D; Vcev. Aleksandar A; Seiwerth. Sven S; Sikiric. Predrag P

Key Findings

  • BPC‑157 (10 µg/kg) reduced bleeding time and hemorrhage in rats after tail amputation, even with heparin or warfarin treatment.
  • BPC‑157 prevented thrombocytopenia (low platelet count) that normally occurs after the injury and anticoagulant use.
  • L‑NAME lowered bleeding but caused thrombocytopenia; L‑arginine increased bleeding without affecting platelets, and BPC‑157 counteracted both of these adverse effects.

Practical Outcomes

  • For biohackers, the data suggest BPC‑157 might help control bleeding and protect platelets, especially when using anticoagulants or during injury. However, the study is in rats, so human dosing and safety are not established. Use with caution, monitor blood work, and treat this as preliminary evidence rather than a proven protocol.

Summary

In rats that had a tail cut, the peptide BPC‑157 consistently shortened bleeding time and reduced blood loss, even when the animals were on strong blood thinners like heparin or warfarin. It also prevented the drop in platelet numbers that usually follows such injuries. By contrast, drugs that block or boost nitric oxide (L‑NAME and L‑arginine) had mixed effects on bleeding and platelets, but BPC‑157 over‑rode those effects.

Abstract

BPC 157 is a stable gastric pentadecapeptide recently implicated with a role in hemostasis. While NO is largely implicated in hemostatic mechanisms, in tail-amputation-models under heparin- and warfarin-administration, both the NO-synthase (NOS)-blocker, L-NAME (prothrombotic) and the NOS-substrate L-arginine (antithrombotic), were little investigated. Objective. To investigate the effect of L-NAME and L-arginine on hemostatic parameters, and to reveal the effects of BPC 157 on the L-NAME- and L-arginine-induced hemostatic actions under different pathological condition: tail amputation without or with anticoagulants, heparin or warfarin. Tail amputation, and/or i.v.-heparin (10 mg/kg), i.g.-warfarin (1.5 mg/kg/day for 3 days) were used in rats. Treatment includes BPC 157, L-NAME, L-arginine, per se and their combination. After (tail) amputation, with or without i.v.-heparin or i.g.-warfarin, BPC 157 (10 μg/kg, 10 ng/kg, i.p., i.v. (heparin), 10 μg/kg i.g. (warfarin)) always reduced bleeding time and/or haemorrhage and counteracted thrombocytopenia. As for L-NAME and/or L-arginine, we noted: L-arginine (100 mg/kg i.p.)-rats: more bleeding, less/no thrombocytopenia; L-NAME (5 mg/kg i.p.)-rats: less bleeding (amputation only), but present thrombocytopenia; L-NAME+L-arginine-rats also exhibited thrombocytopenia: L-NAME counteracted L-arginine-increased bleeding, L-arginine did not counteract L-NAME-thrombocytopenia. All animals receiving BPC 157 in addition (BPC 157 μg+L-NAME; BPC 157 μg+L-arginine, BPC 157 μg+L-NAME+L-arginine), exhibited decreased haemorrhage and markedly counteracted thrombocytopenia. L-NAME (thrombocytopenia), L-arginine (increased haemorrhage) counteraction and BPC 157 (decreased haemorrhage, counteracted thrombocytopenia) with rescue against two different anticoagulants, implicate a BPC 157 modulatory and balancing role with rescued NO-hemostatic mechanisms.

Study Information

Provider

pubmed

Year

2015

Date

2015-04-21T00:00:00.000Z

DOI

10.1371/journal.pone.0123454

Citations

64

References

49